189 related articles for article (PubMed ID: 37369086)
21. Latitude, sun exposure and vitamin D supplementation: associations with quality of life and disease outcomes in a large international cohort of people with multiple sclerosis.
Jelinek GA; Marck CH; Weiland TJ; Pereira N; van der Meer DM; Hadgkiss EJ
BMC Neurol; 2015 Aug; 15():132. PubMed ID: 26243188
[TBL] [Abstract][Full Text] [Related]
22. Towards personalized therapy for multiple sclerosis: prediction of individual treatment response.
Kalincik T; Manouchehrinia A; Sobisek L; Jokubaitis V; Spelman T; Horakova D; Havrdova E; Trojano M; Izquierdo G; Lugaresi A; Girard M; Prat A; Duquette P; Grammond P; Sola P; Hupperts R; Grand'Maison F; Pucci E; Boz C; Alroughani R; Van Pesch V; Lechner-Scott J; Terzi M; Bergamaschi R; Iuliano G; Granella F; Spitaleri D; Shaygannejad V; Oreja-Guevara C; Slee M; Ampapa R; Verheul F; McCombe P; Olascoaga J; Amato MP; Vucic S; Hodgkinson S; Ramo-Tello C; Flechter S; Cristiano E; Rozsa C; Moore F; Luis Sanchez-Menoyo J; Laura Saladino M; Barnett M; Hillert J; Butzkueven H;
Brain; 2017 Sep; 140(9):2426-2443. PubMed ID: 29050389
[TBL] [Abstract][Full Text] [Related]
23. Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years.
Kalincik T; Diouf I; Sharmin S; Malpas C; Spelman T; Horakova D; Havrdova EK; Trojano M; Izquierdo G; Lugaresi A; Prat A; Girard M; Duquette P; Grammond P; Jokubaitis V; van der Walt A; Grand'Maison F; Sola P; Ferraro D; Shaygannejad V; Alroughani R; Hupperts R; Terzi M; Boz C; Lechner-Scott J; Pucci E; Van Pesch V; Granella F; Bergamaschi R; Spitaleri D; Slee M; Vucic S; Ampapa R; McCombe P; Ramo-Tello C; Prevost J; Olascoaga J; Cristiano E; Barnett M; Saladino ML; Sanchez-Menoyo JL; Hodgkinson S; Rozsa C; Hughes S; Moore F; Shaw C; Butler E; Skibina O; Gray O; Kermode A; Csepany T; Singhal B; Shuey N; Piroska I; Taylor B; Simo M; Sirbu CA; Sas A; Butzkueven H;
Neurology; 2021 Feb; 96(5):e783-e797. PubMed ID: 33372028
[TBL] [Abstract][Full Text] [Related]
24. Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis.
Amato MP; Fonderico M; Portaccio E; Pastò L; Razzolini L; Prestipino E; Bellinvia A; Tudisco L; Fratangelo R; Comi G; Patti F; De Luca G; Brescia Morra V; Cocco E; Pozzilli C; Sola P; Bergamaschi R; Salemi G; Inglese M; Millefiorini E; Galgani S; Zaffaroni M; Ghezzi A; Salvetti M; Lus G; Florio C; Totaro R; Granella F; Vianello M; Gatto M; Di Battista G; Aguglia U; Logullo FO; Simone M; Lucisano G; Iaffaldano P; Trojano M
Brain; 2020 Oct; 143(10):3013-3024. PubMed ID: 32935843
[TBL] [Abstract][Full Text] [Related]
25. Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study.
Portaccio E; Bellinvia A; Fonderico M; Pastò L; Razzolini L; Totaro R; Spitaleri D; Lugaresi A; Cocco E; Onofrj M; Di Palma F; Patti F; Maimone D; Valentino P; Confalonieri P; Protti A; Sola P; Lus G; Maniscalco GT; Brescia Morra V; Salemi G; Granella F; Pesci I; Bergamaschi R; Aguglia U; Vianello M; Simone M; Lepore V; Iaffaldano P; Filippi M; Trojano M; Amato MP
Brain; 2022 Aug; 145(8):2796-2805. PubMed ID: 35325059
[TBL] [Abstract][Full Text] [Related]
26. Clinical and laboratory features of in-patients with multiple sclerosis in a University Hospital in Tokyo from 1988-2002.
Tanaka K; Kujuro Y; Suzuki S; Tanahashi N; Hamada J; Nogawa S; Suzuki N
Intern Med; 2005 Jun; 44(6):560-6. PubMed ID: 16020880
[TBL] [Abstract][Full Text] [Related]
27. Epilepsy in multiple sclerosis: A nationwide population-based register study.
Burman J; Zelano J
Neurology; 2017 Dec; 89(24):2462-2468. PubMed ID: 29117950
[TBL] [Abstract][Full Text] [Related]
28. Serious infections in patients with relapsing and progressive forms of multiple sclerosis: A German claims data study.
Knapp R; Hardtstock F; Krieger J; Wilke T; Maywald U; Chognot C; Muros-Le Rouzic E; Craveiro L
Mult Scler Relat Disord; 2022 Dec; 68():104245. PubMed ID: 36306609
[TBL] [Abstract][Full Text] [Related]
29. The use of satellite data to measure ultraviolet-B penetrance and its potential association with age of multiple sclerosis onset.
Amram O; Schuurman N; Randall E; Zhu F; Saeedi J; Rieckmann P; Yee I; Tremlett H
Mult Scler Relat Disord; 2018 Apr; 21():30-34. PubMed ID: 29455071
[TBL] [Abstract][Full Text] [Related]
30. Approaches and challenges in the diagnosis and management of secondary progressive multiple sclerosis: A Central Eastern European perspective from healthcare professionals.
Boyko A; Therapontos C; Horakova D; Szilasiová J; Kalniņa J; Kolontareva J; Gross-Paju K; Selmaj K; Sereike I; Milo R; Gabelić T; Rot U
Mult Scler Relat Disord; 2021 May; 50():102778. PubMed ID: 33592384
[TBL] [Abstract][Full Text] [Related]
31. Multiple sclerosis clinical course and cardiovascular disease risk - Swedish cohort study.
Roshanisefat H; Bahmanyar S; Hillert J; Olsson T; Montgomery S
Eur J Neurol; 2014 Nov; 21(11):1353-e88. PubMed ID: 25041631
[TBL] [Abstract][Full Text] [Related]
32. Onset of secondary progressive phase and long-term evolution of multiple sclerosis.
Scalfari A; Neuhaus A; Daumer M; Muraro PA; Ebers GC
J Neurol Neurosurg Psychiatry; 2014 Jan; 85(1):67-75. PubMed ID: 23486991
[TBL] [Abstract][Full Text] [Related]
33. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.
Tilling K; Lawton M; Robertson N; Tremlett H; Zhu F; Harding K; Oger J; Ben-Shlomo Y
Health Technol Assess; 2016 Oct; 20(81):1-48. PubMed ID: 27817792
[TBL] [Abstract][Full Text] [Related]
34. Parity and disability progression in relapsing-remitting multiple sclerosis.
Achiron A; Ben-David A; Gurevich M; Magalashvili D; Menascu S; Dolev M; Stern Y; Ziv-Baran T;
J Neurol; 2020 Dec; 267(12):3753-3762. PubMed ID: 32725314
[TBL] [Abstract][Full Text] [Related]
35. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.
Brown JWL; Coles A; Horakova D; Havrdova E; Izquierdo G; Prat A; Girard M; Duquette P; Trojano M; Lugaresi A; Bergamaschi R; Grammond P; Alroughani R; Hupperts R; McCombe P; Van Pesch V; Sola P; Ferraro D; Grand'Maison F; Terzi M; Lechner-Scott J; Flechter S; Slee M; Shaygannejad V; Pucci E; Granella F; Jokubaitis V; Willis M; Rice C; Scolding N; Wilkins A; Pearson OR; Ziemssen T; Hutchinson M; Harding K; Jones J; McGuigan C; Butzkueven H; Kalincik T; Robertson N;
JAMA; 2019 Jan; 321(2):175-187. PubMed ID: 30644981
[TBL] [Abstract][Full Text] [Related]
36. Multiple sclerosis by phenotype in Germany.
Engelhard J; Oleske DM; Schmitting S; Wells KE; Talapala S; Barbato LM
Mult Scler Relat Disord; 2022 Jan; 57():103326. PubMed ID: 35158442
[TBL] [Abstract][Full Text] [Related]
37. Seasonal variation of relapse rate in multiple sclerosis is latitude dependent.
Spelman T; Gray O; Trojano M; Petersen T; Izquierdo G; Lugaresi A; Hupperts R; Bergamaschi R; Duquette P; Grammond P; Giuliani G; Boz C; Verheul F; Oreja-Guevara C; Barnett M; Grand'Maison F; Edite Rio M; Lechner-Scott J; Van Pesch V; Fernandez Bolanos R; Flechter S; Den Braber-Moerland L; Iuliano G; Amato MP; Slee M; Cristiano E; Saladino ML; Paine M; Vella N; Kasa K; Deri N; Herbert J; Moore F; Petkovska-Boskova T; Alroughani R; Savino A; Shaw C; Vucic S; Santiago V; Bacile EA; Skromne E; Poehlau D; Cabrera-Gomez JA; Lucas R; Butzkueven H
Ann Neurol; 2014 Dec; 76(6):880-90. PubMed ID: 25283272
[TBL] [Abstract][Full Text] [Related]
38. Application of definitions for conversion to secondary progressive MS in a Danish nationwide population.
Kopp TI; Bramow S; Illes Z; Kant M; Kristensen C; Rasmussen PV; Sellebjerg F; Magyari M
Mult Scler Relat Disord; 2021 Nov; 56():103319. PubMed ID: 34666241
[TBL] [Abstract][Full Text] [Related]
39. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
Filippini G; Del Giovane C; Vacchi L; D'Amico R; Di Pietrantonj C; Beecher D; Salanti G
Cochrane Database Syst Rev; 2013 Jun; (6):CD008933. PubMed ID: 23744561
[TBL] [Abstract][Full Text] [Related]
40. Time interval between the onset of symptoms and diagnosis of multiple sclerosis and the influential factors: A national registry-based study.
Khodaie F; Moghadasi AN; Hosseinnataj A; Baghbanian SM; Ashtari F; Razazian N; Poursadeghfard M; Majdi-Nasab N; Hatamian H; Hoseini S; Nahayati MA; Nabavi SM; Faraji F; Harirchian MH; Mir NHN; Moghadam NB; Sharifipour E; Bayati A; Kamali H; Mozhdehipanah H; Jalali N; Abotorabi-Zarchi M; Kamyari N; Nikbakht R; Azimi A; Navardi S; Heidari H; Sahraian MA; Eskandarieh S
Clin Neurol Neurosurg; 2024 Apr; 239():108221. PubMed ID: 38447483
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
